A high ratio of VEGF-A165b to total VEGF-A at day 30 after percutaneous coronary intervention for acute myocardial infarction was significantly associated with a higher risk of MACCEs.
Observational (n=23)
No
Does a high ratio of VEGF-A165b to total VEGF-A predict major adverse cardiac and cerebrovascular events in patients after acute myocardial infarction treated with primary PCI?
A high ratio of the anti-angiogenic isoform VEGF-A165b to total VEGF-A is associated with an increased risk of major adverse cardiac and cerebrovascular events in patients after acute myocardial infarction.
Absolute Event Rate: 0.87% vs 0.25%
p-value: p=0.0058
Vascular endothelial growth factor-A (VEGF-A) promotes neovascularization and is attracting considerable attention as a remarkable risk factor in patients after acute myocardial infarction (AMI). In contrast, the association between VEGF-A165b, which is the main anti-angiogenic isoform of VEGF-A, and adverse clinical outcomes after AMI remains unclear. The present study aimed to investigate the association between serum VEGF-A165b and major adverse cardiac and cerebrovascular events (MACCEs) after percutaneous coronary intervention (PCI) for AMI. We evaluated 23 patients with AMI who underwent primary percutaneous coronary intervention. VEGF-A and VEGF-A165b levels were measured on admission (day 1) and at days 3, 7, and 30 after PCI. The levels of total VEGF-A tended to be lower, while the ratio of VEGF-A165b to total VEGF-A tended to be higher in patients with MACCEs than in those without. The patients with a high ratio of VEGF-A165b to total VEGF-A had a significantly higher risk of MACCEs using the cut-off values for MACCEs at day 30 after PCI (0.87 vs. 0.25, log-rank test, p = 0.0058). The assessment of VEGF-A165b combined with VEGF-A may be a valuable screening tool for predicting MACCEs in clinical practice.
Harada et al. (Thu,) conducted a observational in Acute myocardial infarction (n=23). High ratio of VEGF-A165b to total VEGF-A vs. Low ratio of VEGF-A165b to total VEGF-A was evaluated on Major adverse cardiac and cerebrovascular events (MACCEs) (p=0.0058). A high ratio of VEGF-A165b to total VEGF-A at day 30 after percutaneous coronary intervention for acute myocardial infarction was significantly associated with a higher risk of MACCEs.